scholarly journals 932Using marginal structural models to account for selection bias in the analysis of legacy effect

2021 ◽  
Vol 50 (Supplement_1) ◽  
Author(s):  
Lin Zhu ◽  
Andrew Hayen ◽  
Katy Bell

Abstract Background Analyses of legacy effects are mainly based on post-trial follow-up study after initial randomized controlled trials (RCT). However, the differential event rates between arms may cause a violation of randomization balance and induce selection bias in the post-trial analysis. We conducted a simulation to illustrate the bias and explore if marginal structural model (MSM) can address it. Methods Our simulation combined an RCT and an extended follow-up study. The scenarios investigated include different settings of direct treatment effect, legacy effect and underlying event rate. To fit the MSM, we used the inverse probability weighting method. The performance of MSM was compared to the standard model with and without adjustment of baseline covariate. Results Post-trial analysis without making adjustment resulted in biased estimates, and the bias increased with the underlying event rate and treatment effect. Both MSM and standard baseline covariate adjustment equally corrected for the bias if no patients took treatment after the trial. We are currently undertaking analysis for scenarios where some people continue treatment post-trial, and there is treatment confounder feedback; these results will be presented at the Congress. Conclusions Estimation of legacy effects using post-trial data without adjusting for differential survival between randomised treatment arms results in biased estimates. Although both standard covariate adjustment and MSM correct the bias if no patients take treatment in the post-trial period, MSM is expected to be the best method in the more realistic scenario where some patients continue to take treatment, and there is treatment confounder feedback. Key messages Post-trial analysis without making adjustment results in biased estimation of legacy effect. Marginal structural models may be used to address the selection bias.

BMJ Open ◽  
2018 ◽  
Vol 8 (9) ◽  
pp. e020584 ◽  
Author(s):  
Agnish Nayak ◽  
Andrew Hayen ◽  
Lin Zhu ◽  
Kevin McGeechan ◽  
Paul Glasziou ◽  
...  

ObjectivesTo assess evidence for ‘legacy’ (post-trial) effects on cardiovascular disease (CVD) mortality and all-cause mortality among adult participants of placebo-controlled randomised controlled trials (RCTs) of statins.DesignMeta-analysis of aggregate data.Setting/ParticipantsPlacebo-controlled statin RCTS for primary and secondary CVD prevention.MethodsData sources: PubMed, Embase from inception and forward citations of Cholesterol Treatment Trialists’ Collaborators RCTs to 16 June 2016.Study selection: Two independent reviewers identified all statin RCT follow-up reports including ≥1000 participants, and cardiovascular and all-cause mortality.Data extraction and synthesis: Two independent reviewers extracted data in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.Main outcomes: Post-trial CVD and all-cause mortality.ResultsWe included eight trials, with mean post-trial follow-up ranging from 1.6 to 15.1 years, and including 13 781 post-trial deaths (6685 CVD). Direct effects of statins within trials were greater than legacy effects post-trials. The pooled data from all eight studies showed no evidence overall of legacy effects on CVD mortality, but some evidence of legacy effects on all-cause mortality (p=0.01). Exploratory subgroup analysis found possible differences in legacy effect for primary prevention trials compared with secondary prevention trials for both CVD mortality (p=0.15) and all-cause mortality (p=0.02). Pooled post-trial HR for the three primary prevention studies demonstrated possible post-trial legacy effects on CVD mortality (HR=0.87; 95% CI 0.79 to 0.95) and on all-cause mortality (HR=0.90; 95% CI 0.85 to 0.96).ConclusionsPossible post-trial statin legacy effects on all-cause mortality appear to be driven by the primary prevention studies. Although these relative benefits were smaller than those observed within the trial, the absolute benefits may be similar for the two time periods. Analysis of individual patient data from follow-up studies after placebo-controlled statin RCTs in lower-risk populations may provide more definitive evidence on whether early treatment of subclinical atherosclerosis is likely to be beneficial.


2009 ◽  
Vol 60 (1) ◽  
pp. 61-68 ◽  
Author(s):  
Mladen Pavlović ◽  
Naima Čorović

An Overview of the 1969-2007 Follow-up Study of Chronic Diseases and Healthy Ageing in Croatia and Pertinent PublicationsThis article brings an overview of data collected in a follow-up study of chronic diseases in general adult population residing in inland and coastal Croatia, that was performed from 1969 to 2007. Despite the selection bias, the sample of volunteers examined in the last follow-up (2005 - 2007), now older than 70, remained as representative as in the previous three follow-ups (1969, 1972, and 1982). Here we report on the design of this prospective cohort study and on papers that have been published as a result. The obtained data could help in promoting healthy living and longevity. The results of our survey might also contribute to the development and implementation of national or international strategies and action plans intended to reduce health risks, and particularly to control and prevent chronic diseases.


2018 ◽  
Vol 25 (3) ◽  
pp. 168-174 ◽  
Author(s):  
Ying Zheng ◽  
Nian-song Wang ◽  
Yu-ning Liu ◽  
Li-qun He ◽  
Gui-hua Jian ◽  
...  

Author(s):  
C. Wolpers ◽  
R. Blaschke

Scanning microscopy was used to study the surface of human gallstones and the surface of fractures. The specimens were obtained by operation, washed with water, dried at room temperature and shadowcasted with carbon and aluminum. Most of the specimens belong to patients from a series of X-ray follow-up study, examined during the last twenty years. So it was possible to evaluate approximately the age of these gallstones and to get information on the intensity of growing and solving.Cholesterol, a group of bile pigment substances and different salts of calcium, are the main components of human gallstones. By X-ray diffraction technique, infra-red spectroscopy and by chemical analysis it was demonstrated that all three components can be found in any gallstone. In the presence of water cholesterol crystallizes in pane-like plates of the triclinic crystal system.


1997 ◽  
Vol 24 (10) ◽  
pp. 713-717 ◽  
Author(s):  
R. NAPANKANGAS ◽  
M.A.M. SALONEN ◽  
A.M. RAUSTIA

2001 ◽  
Vol 120 (5) ◽  
pp. A628-A628
Author(s):  
P CLEMENS ◽  
V HAWIG ◽  
M MUELLER ◽  
J SCAENZLIN ◽  
B KLUMP ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document